Literature DB >> 6110769

Pharmacokinetics of propranolol isomers and their relationships with beta adrenoceptor blocking activity in rabbits administered with dl-propranolol.

K Kawashima, H Ishikawa.   

Abstract

Plasma concentrations of dl- and l-propranolol were determined in rabbits after the i.v. injection of 200, 400 and 800 micrograms/kg of dl-propranolol. The data conformed to a biexponential equation. The beta adrenoceptor blocking activity was measured by the percent reduction in isoproterenolol-induced tachycardia after the administration of dl-propranolol. The l-isomer had a longer plasma half-life than dl-propranolol at each dose during the beta-phase. At a dose of 800 micrograms/kg, both dl- and l-propranolol had longer plasma half-life than those of 200 and 400 micrograms/kg doses and a smaller total plasma clearance was observed to 800 micrograms/kg, although statistically not significant. At steady state, plasma concentrations of both dl- and l-propranolol correlated well with beta adrenoceptor blocking activity (r = 0.913 for dl-propranolol and r = 0.939 for the l-isomer). These results demonstrate that after the administration of the racemic drug l-propranolol had a longer plasma half-life. The plasma concentration of dl- and l-propranolol is a good parameter for beta adrenoceptor blocking activity. The pharmacologic activity of propranolol at the highest dose persists longer than expected, probably due to hemodynamic alterations, which causes a decrease in liver blood flow with the resultant reduction in the elimination rate of the drug.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6110769

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

1.  Pharmacokinetics and dynamics of penbutolol in humans: evidence for pathway-specific stereoselective clearance.

Authors:  H R Ochs; P Hajdú; D J Greenblatt
Journal:  Klin Wochenschr       Date:  1986-07-15

2.  Stereoselective binding of propranolol enantiomers to human alpha 1-acid glycoprotein and human plasma.

Authors:  F Albani; R Riva; M Contin; A Baruzzi
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

3.  Pharmacokinetics and pharmacodynamics of propranolol stereoisomers in hyperthyroid patients.

Authors:  K Tawara; K Kawashima; H Ishikawa; K Yamamoto; K Saito; A Ebihara; S Yoshida
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.